ExploreWatchlistsPricing
  1. JP-listed companies
  2. BrightPath Biotherapeutics Co., Ltd.
  3. Financials
  4. Cost of revenue

BrightPath Biotherapeutics Co., Ltd. (4594)

Market cap
¥4.9B
P/E ratio
-3.9x
Brightpath Bio develops novel cancer immunotherapy drugs including cell therapies, antibodies, and personalized vaccines, licensing them to pharmaceutical partners worldwide.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndCost of revenue (Million JPY)YoY (%)
Mar 31, 20260-9.38%
Mar 31, 20250+77.78%
Mar 31, 20240-99.05%
Mar 31, 20232-42.87%
Mar 31, 20223+189.69%
Mar 31, 20211-74.37%
Mar 31, 20204-93.68%
Mar 31, 201971-77.57%
Mar 31, 2018315-39.96%
Mar 31, 2017525-31.98%
Mar 31, 2016772+0.66%
Mar 31, 2015767

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat